Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

For the month ended:	30 June 2022	Status:	New Submission
To : Hong Kong Exchanges	and Clearing Limited		
Name of Issuer:	Innovent Biologics, Inc.		
Date Submitted:	07 July 2022		

## I. Movements in Authorised / Registered Share Capital

1. Type of shares	Ordinary shares	Class of shares		Not appl	icable		Listed on SEHK (No	ote 1)	Yes	
Stock code	01801		Description	Ordinary	shares					
		Number of	f authorised/registere	Par value			Authorised/registered share capital			
Balance at close of preceding month			5,000	5,000,000,000 USD		0.00001		USD	50,0	
Increase / decrease (-)		0				USD				
Balance at close of the month5,000,00			),000,000	USD		0.00001	USD		50,000	

Total authorised/registered share capital at the end of the month:	USD	50,000
--	-----	--------

### **II.** Movements in Issued Shares

1. Type of shares	Ordinary shares		Class of shares	Not applicable	Listed on SEHK (Note 1)	Yes	
Stock code	01801		Description	Ordinary shares			
Balance at close of preceding month			1,466,789,451				
Increase / decrease (-)		657,500					
Balance at close of the month		1,467,446,951					

### III. Details of Movements in Issued Shares

(A). Share Options (under Share Option Schemes of the Issuer)

1. Type of shares issuable Ordinary shares		Clas	Class of shares Not applic		ıble	Shar	hares issuable to be listed on SEHK (Note 1)				
Sto	ck code of shares issuable	e (if listed on SEHK) (Note	1) 0180	)1					•		
Ра	Particulars of share option scheme Scheme Number of share options outstanding at close of preceding month		Move	Movement during the month		Number of share opt outstanding at close the month				eto	
1).	Pre-IPO Share Incentive Plan	40,565,583	Granted			39,82	3,083	657,500	27,509,33	3	0
			Exercised	ised -65					l		
		-	Cancelled		-85,000						
			Lapsed								
	eral Meeting approval e (if applicable)	10 May 2012									
2).	Post-IPO share option	95,660,260 G	Granted		117,045	94,91	7,590	0 0	9,525,669	9	13,650,235
	scheme	-	Exercised								
		-	Cancelled	ancelled -859							
		-	_apsed								
	eral Meeting approval e (if applicable)	12 June 2018					l				
					T	otal A (Ordinary shar	res):	657,500			
	Total funds raised during the month from exercise of options: HKD 742,993.43										

Remarks:

1). During the month, 37,500 share options granted under the Pre-IPO Share Incentive Plan were vested and 85,000 unvested share options granted under the Pre-IPO Share Incentive Plan were cancelled. After deducting the exercised 657,500 share options, the number of new shares of the Company which may be issued pursuant to the vested and exercisable share options granted under the plan as the close of the month is 27,509,333 shares.

2) During the month, 724,282 share options granted under the Post-IPO share option scheme were vested and 859,715 unvested share options granted under the Post-IPO share option scheme were cancelled. The number of new shares of the Company which may be issued pursuant to the vested and exercisable share options granted under the plan as the close of the month is

#### 9,525,669 shares.

(B). Warrants to Issue Shares of the Issuer which are to be Listed Not applicable

(C). Convertibles (i.e. Convertible into Issue Shares of the Issuer which are to be Listed) Not applicable

#### (D). Any other Agreements or Arrangements to Issue Shares of the Issuer which are to be listed, including Options (other than Share Options Schemes)

1.	Type of shares issuable	Ordinary shares	Class of shares	Not a	Not applicable		Shares issuable to be listed on SEHK (Note 1)		Yes	
St	Stock code of shares issuable (if listed on SEHK) (Note 1) 01801									
	Description				General Meeting approval date (if applicable)	No. c	of new shares of issuer issued during the month pursuant thereto (D)	No. of new issued purs	shares of issu suant thereto a month	er which may be s at close of the
1).	1). Innovent Biologics, Inc. 2018 Restricted Share Plan (has been terminated)				15 October 2018		0			0
2). Innovent Biologics, Inc. 2020 Restricted Share Plan				12 June 2020		0			0	

Total D (Ordinary shares):

0

#### Remarks:

During the month, 123,816 restricted shares granted under the Innovent Biologics, Inc. 2018 Restricted Share Plan were cancelled.
During the three months, a total of 344,016 restricted shares granted under the Innovent Biologics, Inc. 2020 Restricted Share Plan were cancelled. 14,631 restricted shares were granted under the Innovent Biologics, Inc. 2020 Restricted Share Plan were cancelled.

(E). Other Movements in Issued Share Not applicable

Total increase / decrease (-) in Ordinary shares during the month (i.e. Total of A to E)	657,500

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

# V. Confirmations

	e hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued by the issuer during the month as set out in Part III and IV which has not been eviously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and, insofar as applicable:							
(Note 2)								
(i) all money due to the li	Il money due to the listed issuer in respect of the issue of securities has been received by it;							
(ii) all pre-conditions for I	isting imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled;							
(iii) all (if any) conditions	contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;							
(iv) all the securities of ea	ach class are in all respects identical (Note 3);							
	(v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;							
(vi) all the definitive docu	ments of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;							
	n place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase such property has been duly satisfied; and							
(viii) the trust deed/deed Registrar of Compa	poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the nies.							
Submitted by:	Yanju Wang							

Title:

Joint Company Secretary

(Director, Secretary or other Duly Authorised Officer)

#### Notes

1. SEHK refers to Stock Exchange of Hong Kong.

2. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, no further confirmation is required to be made in this return.

- 3. "Identical" means in this context:
  - the securities are of the same nominal value with the same amount called up or paid up;
  - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
  - . they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
- 4. If there is insufficient space, please submit additional document.
- 5. In the context of repurchase of shares:
  - . "shares issuable to be listed on SEHK" should be construed as "shares repurchased listed on SEHK"; and
  - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares repurchased (if listed on SEHK)"; and
  - . "type of shares issuable" should be construed as "type of shares repurchased"; and
  - . "issue and allotment date" should be construed as "cancellation date"
- 6. In the context of redemption of shares:
  - . "shares issuable to be listed on SEHK" should be construed as "shares redeemed listed on SEHK"; and
  - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares redeemed (if listed on SEHK)"; and
  - . "type of shares issuable" should be construed as "type of shares redeemed"; and
  - . "issue and allotment date" should be construed as "redemption date"